Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Ester Siemerink, Hedwig M. Blommestein, Danny Houtsma, Vincent van der Noort et al.
Citations
2 citations
Journal
European Journal of Cancer
Topics
Advanced Breast Cancer Therapies
Field-Weighted Citation Impact (FWCI)
3.04
article
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Ester Siemerink, Hedwig M. Blommestein, Danny Houtsma, Vincent van der Noort, Annemieke van der Padt‐Pruijsten, Gabe S. Sonke, A. Elise van Leeuwen‐Stok, F. Van den Berkmortel, Hendrika M. Oosterkamp, Helga Droogendijk, Agnes Jager, Annette A. van Zweeden, Marlies L. van Bekkum, E. van den Pol, Cristina Guerrero Páez, Annemiek van Ommen‐Nijhof, Noor Wortelboer, Inge R. Konings, Jolien Tol, Seamus Kent
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
European Journal of CancerVol. 231
Institutions
Dutch Cancer Society (NL), Amsterdam UMC Location University of Amsterdam (NL), The Netherlands Cancer Institute (NL), Medisch Centrum Haaglanden (NL), Borstkankervereniging Nederland (NL), Maasstad Ziekenhuis (NL), Zuyderland Medisch Centrum (NL), Netherlands Comprehensive Cancer Organisation (NL), Haga Hospital (NL), Ziekenhuis Amstelland (NL), Ziekenhuis Groep Twente (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Jeroen Bosch Ziekenhuis (NL), Bravis Ziekenhuis (NL), University of Amsterdam (NL), Erasmus University Rotterdam (NL), Delft University of Technology (NL)